Stockscreener 앱 받기
28.80
0.35%
-0.10
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks
IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan
IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan
IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan
IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace
IDEAYA to file NDA for uveal melanoma drug under FDA fast review - Investing.com Canada
Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting - Stock Titan
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN
IDEAYA Biosciences Advances Precision Oncology with AI Discovery - HarianBasis.co
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Insider Monkey
IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading.Pro Level Trade Signals - Xã Thanh Hà
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - MSN
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - BioSpace
IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st
IDEAYA to present trial data at ASCO meeting in June By Investing.com - Investing.com Australia
IDEAYA to present trial data at ASCO meeting in June - Investing.com
Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%Here's Why - MarketBeat
Why IDEAYA Biosciences Stock Is Suddenly Sinking - TipRanks
IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan
Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IDEAYA Biosciences Inc : JP Morgan Raises Tar - Moomoo
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - Sahm
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Wedbush Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - The Malaysian Reserve
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
Oppenheimer raises Ideaya Biosciences price target on trial data By Investing.com - Investing.com Canada
Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality - Seeking Alpha
Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
0.14%
0.48%
자본화:
|
볼륨(24시간):